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Available online 22 May 2020HIV drug resistance testing before initiation of antiretroviral treat-
ment has been demonstrated to have clinical benefits in epidemio-
logical studies across sub-Saharan Africa [13]. The largest
epidemiological study on antiretroviral drug resistance in Africa was
the PharmAccess African Studies to Evaluate Resistance Monitoring
(PASER-M) which included 2579 individuals between 2007 and 2009
from six African countries [1,2]. PASER-M found that, compared to
patients in whom no drug resistance was found, individuals infected
with a drug resistant virus were twice as likely to experience virolog-
ical failure after twelve months [1], and four times more likely to
switch to a second-line regimen within three years [2]. Pre-treatment
drug resistance was not associated with increased mortality or new
AIDS events [2]. Although PASER-M provided important insights,
more than 50% of the study participants used zidovudine or stavu-
dine which are no longer recommended antiretroviral drugs. In this
respect it is important to observe that a recent study from Kenya, in
which participants used currently recommended drugs, found that
guiding treatment based on drug resistance testing reduced virologi-
cal failure by 1.2% and mortality by 1.8%, which was not statistically
significant [3]. Patients are, however, unable to take advantage of
these potential clinical benefits when a drug resistance test is not
performed due to health system financial constraints.
In eClinicalMedicine, Duarte and colleagues modelled the cost-
effectiveness of baseline resistance testing using two types of assays:
a traditional consensus sequencing assay, and a low-cost point-muta-
tion assay [4]. The authors concluded that pre-treatment drug resis-
tance testing is unlikely to be cost-effective in Kenya given the
current NNRTI-based first-line regimen used among women. Should
Kenyan women switch to a dolutegravir-based first-line regimen inDOI of original article: http://dx.doi.org/10.1016/j.eclinm.2020.100347.
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sidered cost-effective.
New antiretroviral drugs are, however, continuously being devel-
oped. In the coming years, long-acting antiretroviral drugs can
become available which allow less frequent dosing and thereby
reducing the burden of daily therapy. Of the long-acting formulations
that are currently being developed, the two-drug injectable combina-
tion of cabotegravir and rilpivirine is in the most advanced stage of
development [5,6]. New modeling studies should be performed in
the future to assess the cost-effectiveness of pre-treatment drug
resistance when long-acting antiretroviral drugs become available.
Even if new regimens and ART formulations become available, there
may be other nuanced effects of implementing pre-treatment resistance
testing, regardless of current or future regimen type. In particular, same-
day ART initiation has become widely recommended to the majority of
patients with a newly confirmed HIV diagnosis. Same-day ART initiation
has been shown to increase uptake of ART by up to 36% [7,8]. Therefore, a
delay in ART initiation due to waiting of results from a pre-treatment
drug resistance results could result in a decrease in the proportion of peo-
ple initiating ART, further hampering epidemic control.
Duarte and colleagues addressed HIV drug resistance as part of
clinical care. HIV drug resistance testing, however, is also used for
surveillance purposes in which the occurrence of resistance associ-
ated mutations is studied in a sample of people living with HIV that
initiate treatment or who showed virological failure while on antire-
troviral therapy. These surveillance programs allow the timely identi-
fication of wide-spread transmission and emergence of drug
resistance which in turn could necessitate a change in treatment [6].
As a consequence, surveillance programs using drug resistance test-
ing should be continued as part of public health programs.
The study by Duarte and colleagues further adds to the body of
evidence that, given the regimens available now and the current rates
of transmitted drug resistance, pre-treatment drug resistances test-
ing is unlikely to be cost-effective. Resources should instead continue
to focus on consistent annual viral load monitoring and a timely
switch to second-line regimen if required.
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